Sep 14, 2010
$93,000 is a lot of money, but this tidy sum is the cost of a full treatment with Dendreon’s new prostate cancer therapeutic vaccine, Provenge™[1]. The new treatment, recently approved by the FDA[2], is indicated for use in minimally symptomatic, hormone refractory (androgen-independent), metastatic prostate cancer. In such seriously ill patients, this...